azercabtagene zapreleucel

{
  "id": "MLC-T-ONC-011847",
  "term": "azercabtagene zapreleucel",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) with potential immunostimulating and antineoplastic activities. Upon administration, azercabtagene zapreleucel specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.",
  "synonyms": [
    "allogeneic anti-CD19-CAR T lymphocytes PBCAR0191",
    "anti-CD19-CAR allogeneic T cells PBCAR0191",
    "allogeneic anti-CD19-CAR T-cells PBCAR0191",
    "allogeneic anti-CD19-CAR T-lymphocytes PBCAR0191",
    "anti-CD19-CAR allogeneic T-cells PBCAR0191"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/azercabtagene-zapreleucel/"
}